ClinicalTrials.gg
RecruitingNCT06004856Updated May 13, 2024

Evaluate the Efficacy and Safety of Orelabrutinib in Adult Patients With Chronic Primary Immune Thrombocytopenia

A Phase 3 interventional study of Orelabrutinib and Placebo in Chronic Primary Immune Thrombocytopenia (ITP), sponsored by Beijing InnoCare Pharma Tech Co., Ltd.. Recruiting at 45 sites in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2024-05-13.

Sponsored by Beijing InnoCare Pharma Tech Co., Ltd. (part of InnoCare Pharma Limited) · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Dec 2025, 10 months ago, but the record still lists the study as recruiting.
  • Started Oct 2023; still recruiting 3 years later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
195
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 185 studies in Purpura, Thrombocytopenic, Idiopathic with a site in China — 82 open to participants now, 92 under way, 12 of them phase 3. Purpura, Thrombocytopenic, Idiopathic · China.

Planned enrollment
23rd of 167
195 · median 62
Started
2023
with 18 others
Phase 3
39 of 185
7 open now
Primary completion
2025-12
later than 26 of 91 live
Registered
111th of 185
by date

Among the 185 studies in Purpura, Thrombocytopenic, Idiopathic with a site in China, this one is the 23rd largest by planned enrollment of the 167 interventional ones that give a count, is one of 19 that started in 2023, is one of 39 in phase 3, reaches primary completion later than 26 of the 91 other live ones, and was the 111th registered.

Purpura, Thrombocytopenic, Idiopathic

504 studies on the registry are indexed under Purpura, Thrombocytopenic, Idiopathic; 159 are open to participants now.

Browse Purpura, Thrombocytopenic, Idiopathic studies →

Open to participants now

82 of the 185 studies in Purpura, Thrombocytopenic, Idiopathic with a site in China are open now. Recruiting first, the newest first:

77 more — sign in →

All 82 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 103 Purpura, Thrombocytopenic, Idiopathic studies recruiting now, 49 (48%) set no upper age limit and 42 (41%) stop at 75 or younger; 27 take children under 18; 4 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 185 studies in Purpura, Thrombocytopenic, Idiopathic with a site in China, or all of them as a file.
02

Study summary

A Randomized, Double-blind, Placebo-controlled Phase III Clinical Study to Evaluate the Efficacy and Safety of Orelabrutinib in Adult Patients with Chronic Primary Immune Thrombocytopenia

03

Conditions studied

  • Chronic Primary Immune Thrombocytopenia (ITP)
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subjects have had a detailed understanding of the nature, significance, possible benefits, possible inconveniences, and potential risks of the trial, understood the study procedures, and voluntarily signed a written ICF before the study.
  2. Males or females aged from 18 to 80 years (including the marginal values).
  3. With a body weight of ≥ 35 kg at screening.
  4. In accordance with the diagnosis of chronic (≥ 12 months) ITP
  5. Patients who have previously received at least one anti-ITP standard treatment ( and/or intravenous immunoglobulin) cannot maintain efficacy, or relapse, or cannot tolerate standard treatment, or have insufficient response.
  6. Females of must use an effective method of during the screening period, throughout the entire trial, and for 90 days after the last administration of the medicinal product (IMP).

Exclusion criteria

Exclusion Criteria:

  1. Severe hemorrhage occurred within 4 weeks prior to screening.
  2. Subjects suffered from severe ITP at screening and were not eligible for participation in this study as judged by the investigator.
  3. Subjects had systemic diseases other than ITP unless they would not affect the evaluation of the study results in the judgment of the investigator and sponsor medical monitor.
  4. Subjects had multiple immune hemocytopenia.
  5. Subjects had inherited thrombocytopenia or secondary ITP.
  6. Subjects had a history of arterial or venous thromboembolism within 6 months prior to screening.
  7. Received prohibited medications within protocol-specified period before the first dose.
  8. Received blood transfusion (including transfusion) within 2 weeks prior to the first dose of the drug.
  9. Participated in another study of the investigational drug (and/or investigational device) within 30 days or within 5 half-lives prior to screening (whichever is longer), or is currently participating in another study of the investigational drug (and /or investigational device).
  10. The last administration of strong inhibitors or strong CYP3A inducers (include food, western medicine, traditional Chinese medicine) is within 14 days (or 5 half-lives, whichever is longer) prior to the first dose, or planned to take a drug or food with a strong inhibition or induction of CYP3A during the study period.
  11. Received a major surgery (including splenectomy) or trauma (except ) within 28 days prior to the first dose of the investigational drug, or expected to receive a major surgery during the study treatment period.
  12. Received splenectomy and had a prior history of overwhelming post-splenectomy infection (OPSI).
  13. Had a history of alcohol or drug abuse currently or within the past 1 year, excepting nicotine and caffeine.
  14. Received a COVID-19 vaccine, , or live-attenuated vaccine within 1 month prior to screening or during the screening period.
  15. Previous exposure to BTK inhibitors.
  16. Laboratory results did not meet protocol requirements.
  17. Pregnant or lactating women.
  18. Subjects whose blood cannot be collected, or who had for blood collection.
  19. Other conditions that were not appropriate for participation in the trial as considered by the investigators.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
195 participants (estimated)

Study arms

  • Experimental
    Orelabrutinib

    Drug: Orelabrutinib

  • Placebo comparator
    Placebo

    Drug: Placebo

Interventions

  • Orelabrutinib once daily (QD)

  • DrugPlacebo

    Placebo once daily (QD)

06

What researchers measure

Primary outcomes

  1. Durable response rate

    Time frame: Throughout the study period, an average of 6 months

07

Study locations

25 of 45 sites recruiting
  • The first affiliated hospital of bengbu medical college
    Bengbu, Anhui 233004, China
    Recruiting
    • Feng Zhang · Contact
  • The First Affiliated Hospital of Anhui Medical University
    Hefei, Anhui 230022, China
    Recruiting
    • Qingshu Zeng · Contact
  • Beijing CHAO-YANG Hospital Capital Medcal University
    Beijing, Beijing 100044, China
    Recruiting
    • Wenming Chen · Contact
  • Peking university People's Hospital
    Beijing, Beijing 100044, China
    Not yet recruiting
    • Xiaohui Zhang · Contact
  • Xinqiao Hospital of Army Medical University
    Chongqing, Chongqing 400000, China
    Not yet recruiting
    • Yimei Feng · Contact
  • Fujian Medical University Union Hospital
    Fuzhou, Fujian 350001, China
    Not yet recruiting
    • Fenge Yang · Contact
  • The First Affiliated Hospital of Xiamen University
    Xiamen, Fujian 361004, China
    Not yet recruiting
    • Bing Xu · Contact
  • Zhongshan Hospital Xiamen University
    Xiamen, Fujian 361004, China
    Not yet recruiting
    • Quanyi Lu · Contact
  • Gansu Provincial Hospital
    Lanzhou, Gansu 730000, China
    Recruiting
    • Qike Zhang · Contact
  • Nanfang Hospital, Southern Medical University
    Guangzhou, Guangdong 510515, China
    Recruiting
    • Jing Sun · Contact
  • Huazhong University of Science and Technology Union Shenzhen Hospital
    Shenzhen, Guangdong 518052, China
    Recruiting
    • Zhi Guo · Contact
  • The Second Hospital of Hebei Medical University
    Shijiazhuang, Hebei 050000, China
    Recruiting
    • Jingyu Zhang · Contact
  • North China University of Science and Technology Affiliated Hospital
    Tangshan, Hebei 063000, China
    Not yet recruiting
    • Zhenyu Yan · Contact
  • The Second Affiliated Hospital of Harbin Medical University
    Harbin, Heilongjiang 150001, China
    Not yet recruiting
    • Wei Wang · Contact
  • The First Affiliated Hospital of Henan University of Science and Technology
    Luoyang, Henan 471000, China
    Recruiting
    • Ling Qin · Contact
  • Henan Cancer Hospital
    Zhengzhou, Henan 450004, China
    Recruiting
    • Hu Zhou · Contact
  • The First Affiliated Hospital of Zhengzhou University
    Zhengzhou, Henan 450052, China
    Recruiting
    • Fang Wang · Contact
  • Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
    Wuhan, Hubei 430022, China
    Recruiting
    • Heng Mei · Contact
  • Tongji Medical College Of Hust
    Wuhan, Hubei 430030, China
    Not yet recruiting
    • Dengju Li · Contact
  • Yichang Central People's Hospital
    Yichang, Hubei 443008, China
    Recruiting
    • Jingming Guo · Contact
  • Xiangya Hospital Central South University
    Changsha, Hunan 410008, China
    Not yet recruiting
    • Yajing Xu · Contact
  • Chenzhou First People's Hospital
    Chenzhou, Hunan 423003, China
    Recruiting
    • Xinquan Liang · Contact
  • The Central Hospital of Yongzhou
    Yongzhou, Hunan 425006, China
    Recruiting
    • Shibin Deng · Contact
  • Affiliated Hospital of Inner Mongolia Medical University
    Hohhot, Inner Mongolia 010000, China
    Not yet recruiting
    • Da Guo · Contact
  • Nanjing Drum Tower Hospital
    Nanjing, Jiangsu 210000, China
    Not yet recruiting
    • Rongfu Zhou · Contact
  • Jiangsu Province Hospital
    Nanjing, Jiangsu 210029, China
    Not yet recruiting
    • Guangsheng He · Contact
  • Wuxi People's Hospital
    Wuxi, Jiangsu 214000, China
    Recruiting
    • Xin Zhou · Contact
  • Jiangxi Provincial People's Hospital
    Nanchang, Jiangxi 330006, China
    Recruiting
    • Chenghao Jin · Contact
  • The First Affiliated Hospital of Nanchang University
    Nanchang, Jiangxi 330006, China
    Recruiting
    • Ruibin Huang · Contact
  • The first Hospital of China Medical University
    Shenyang, Liaoning 110002, China
    Not yet recruiting
    • Xiaojing Yan · Contact
  • Qilu Hospital Of Shandong University Dezhou Hospital
    Dezhou, Shandong 253000, China
    Not yet recruiting
    • Lin Wang · Contact
  • Qilu hospital of shandong university
    Jinan, Shandong 250012, China
    Recruiting
  • Ruijin Hospital, Shanghai Jiao Tong University School of Medicine
    Shanghai, Shanghai 200020, China
    Not yet recruiting
    • Junmin Li · Contact
  • Xi'an Central Hospital
    Xi'an, Shanxi 710003, China
    Recruiting
    • Yanping Song · Contact
  • The First Affiliated Hospital of Xi 'an Jiaotong University
    Xi'an, Shanxi 710061, China
    Not yet recruiting
    • Pengcheng He · Contact
  • Shaanxi Provincial People'S Hospital
    Xi'an, Shanxi 710068, China
    Recruiting
    • Yi Wang · Contact
  • Sichuan Provincial People's Hospital
    Chengdu, Sichuan 610000, China
    Recruiting
    • Rong Xiao · Contact
  • The Affilated Hospital of Southwest Medical University
    Luzhou, Sichuan 646000, China
    Not yet recruiting
    • Xiaoming Li · Contact
  • The Second People's Hospital of Yibin
    Yibin, Sichuan 644000, China
    Not yet recruiting
    • Shihua Huang · Contact
  • Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences
    Tianjin, Tianjin 300020, China
    Recruiting
    • Lei Zhang · Contact
  • Tianjin Medical University General Hospital
    Tianjin, Tianjin 300052, China
    Not yet recruiting
    • Rong Fu · Contact
  • The First Affiliated Hospital of Xinjiang Medical University
    Ürümqi, Xinjiang Uygur Autonomous Region 830000, China
    Not yet recruiting
    • Xinhong Guo · Contact
  • The Second Affiliated Hospital of Kunming Medical University
    Kunming, Yunnan 650000, China
    Recruiting
    • Zeping Zhou · Contact
  • The First Affiliated Hospital Zhejiang University School of Medicine
    Hangzhou, Zhejiang 310000, China
    Recruiting
    • Jie Jin · Contact
  • Zhejiang Provincial Hospital of Chinese Medicine
    Hangzhou, Zhejiang 310000, China
    Recruiting
    • Baodong Ye · Contact
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2023 (actual). Primary completion is estimated for Dec 2025, 26 months after the start.

Of 41 industry-sponsored phase 3 interventional studies under Purpura, Thrombocytopenic, Idiopathic, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 44. This study's planned 26 months is close to that.

Counting every sponsor, half of 57 studies reached it within 28 months; a quarter within 22 and three quarters within 49.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 15, 2023
First posted
Aug 22, 2023
StartActual
Oct 26, 2023
Primary completionEst.
Dec 31, 2025
CompletionEst.
Apr 30, 2026
Last update
May 13, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 13, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06004856
Responsible party
Sponsor
First posted
Aug 22, 2023
Start date
Oct 26, 2023
Primary completion
Dec 31, 2025 (estimated)
Completion
Apr 30, 2026 (estimated)
Last update
May 13, 2024

Study contacts

Alexia Lu
Contact
CO_HGRAC@innocarepharma.com
010-66609745

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Orelabrutinib

Start the discussion